P15692 (VEGFA_HUMAN) Homo sapiens (Human)
Vascular endothelial growth factor A, long form UniProtKBInterProInteractive Modelling
395 aa; Sequence (Fasta) ; (Isoform 1; Isoform 2; Isoform 3; Isoform 4; Isoform 5; Isoform 6; Isoform 8; Isoform 9; Isoform 10; Isoform 11; Isoform 12; Isoform 14; Isoform 15; Isoform 16; Isoform 17; Isoform 18)
Available Structures
54 Experimental Structures
| Description | PDB ID | Oligo-state | Range | Seq id (%) | Ligands | |
|---|---|---|---|---|---|---|
| Dual-acting Fab 5A12 in complex with VEGF |
Heteromer | 100 | 1×SO4; | |||
| D-Protein RFX-V2 Bound to the VEGFR1 Domain 3 Site on VEGF-A |
Heteromer | 100 | ||||
| The structure of Raamsizumab in complex with VEGF121 |
Heteromer | 100 | 1×NAG; 1×NAG; | |||
| Solution Structure of a Phage-Derived Peptide Antagonist in Complex with Vascular Endothelial Growt… |
Heteromer | 100 | ||||
| VEGF IN COMPLEX WITH DOMAIN 2 OF THE FLT-1 RECEPTOR |
Heteromer P17948; | 100 | ||||
| Crystal structure of hVEGF in complex with VK domain antibody |
Heteromer | 100 | ||||
| Structure of the B20-4 Fab, a phage derived Fab fragment, in complex with VEGF |
Heteromer | 100 | ||||
| Crystal structure of an engineered lipocalin (Anticalin) in complex with VEGF(8-109) |
Heteromer P31025; | 100 | 2×OMA; 3×SO4; 1×ACT; | |||
| D-Protein RFX-V1 Bound to the VEGFR1 Domain 2 Site on VEGF-A |
Heteromer | 100 | ||||
| Crystal Structure of the Fab YADS2 Complexed with h-VEGF |
Heteromer | 100 | ||||
| Crystal structure of hVEGF in complex with VH domain antibody |
Heteromer | 100 | ||||
| Structure of VEGF complexed to a Fab containing TYR and SER in the CDRs |
Heteromer | 100 | ||||
| COMPLEX BETWEEN VEGF AND A RECEPTOR BLOCKING PEPTIDE |
Heteromer | 100 | ||||
| Crystal structure of an engineered human autonomous VH Domain in complex with VEGF |
Heteromer | 100 | ||||
| The Development of Peptide-based Tools for the Analysis of Angiogenesis |
Heteromer | 100 | ||||
| Crystal structure of a bispecific DutaFab in complex with human VEGF121 |
Heteromer | 100.0 | ||||
| Crystal structure of VEGF-A in complex with VEGFR-1 domains D1-6 |
Heteromer P17948; | 100 | 2×NAG; 19×NAG; | |||
| Crystal Structure of Chemically Synthesized Heterochiral {D-Protein Antagonist plus VEGF-A} Protein… |
Heteromer | 100 | 1×PEG; 1×GOL; | |||
| Crystal Structure of Chemically Synthesized Heterochiral {D-Protein Antagonist plus VEGF-A} Protein… |
Heteromer | 100 | ||||
| Crystal Structure of Chemically Synthesized Heterochiral {RFX037 plus VEGF-A} Protein Complex in sp… |
Heteromer | 100 | 2×GOL; | |||
| Crystal Structure of Chemically Synthesized Heterochiral {RFX037 plus VEGF-A} Protein Complex in sp… |
Heteromer | 100 | 3×GOL; | |||
| Crystal structure of VEGF in complex with heterodimeric Fcab JanusCT6 |
Heteromer P0DOX5; | 98.95 | 2×NAG; 1×MAN; 1×NAG; 10×MPD; 1×MRD; 2×CAC; 1×TRS; | |||
| Crystal structure of bH1 Fab variant (CDR H3 loop design 13_0346) in complex with VEGF |
Heteromer | 100 | 2×EDO; 1×CL; | |||
| Crystal structure of bH1 Fab variant (CDR H3 loop design 14_0130) in complex with VEGF |
Heteromer | 100 | 8×CL; | |||
| Structure of Bevacizumab Fab mutant in complex with VEGF |
Heteromer P0DOX5; Q8TCD0; | 100 | 2×SO4; 2×MES; | |||
| The Development of Peptide-based Tools for the Analysis of Angiogenesis |
Heteromer | 100 | ||||
| VASCULAR ENDOTHELIAL GROWTH FACTOR IN COMPLEX WITH DOMAIN 2 OF THE FLT-1 RECEPTOR |
Heteromer P17948; | 100 | ||||
| Structure of the G6 Fab, a phage derived Fab fragment, in complex with VEGF |
Heteromer | 100 | 7×SO4; | |||
| Vascular endothelial growth factor in complex with alpha/beta-VEGF-1 |
Heteromer | 100 | ||||
| VEGFR-2/VEGF-A COMPLEX STRUCTURE |
Heteromer P35968; | 100 | ||||
| Crystal structure of bH1 Fab variant (CDR H3 loop design 16_0325) in complex with VEGF |
Heteromer | 100 | 2×CL; | |||
| VASCULAR ENDOTHELIAL GROWTH FACTOR IN COMPLEX WITH AN AFFINITY MATURED ANTIBODY |
Heteromer | 100 | 2×SO4; | |||
| VASCULAR ENDOTHELIAL GROWTH FACTOR IN COMPLEX WITH A NEUTRALIZING ANTIBODY |
Heteromer | 100 | 2×SO4; | |||
| Crystal Structure of the Fab YADS1 Complexed with h-VEGF |
Heteromer | 100 | ||||
| Human NRP2 b1 domain in complex with the peptide corresponding to the C-terminus of VEGF-A |
Heteromer O60462; | 100 | ||||
| The crystal structure of chemically synthesized VEGF-A | homo-2-mer | 100 | 2×ACT; 4×TFA; 2×GOL; | |||
| Crystal Structure of Vascular Endothelial Growth Factor (VEGF8-109) with HH4, an alpha/beta-Peptide… | homo-2-mer | 96.88 | ||||
| High resolution structure of VEGF-A 12:107 crystallized in tetragonal form | homo-2-mer | 100 | 4×MPD; 3×PO4; | |||
| VEGF-A 13:107 crystallized with 4C bicyclic peptide | homo-2-mer | 100 | 5×MPD; 1×PO4; | |||
| crystal structure of human VEGF-A receptor binding domain | homo-2-mer | 100 | 2×NAG; 2×PGE; 2×SO4; | |||
| VEGF-A 13:107 crystallized with 3C bicyclic peptide | homo-2-mer | 100 | 1×NH2; 5×ACY; 2×MPD; | |||
| VEGF-A 13:107 crystallized with 1C bicyclic peptide | homo-2-mer | 100 | 5×MPD; 1×PO4; | |||
| VASCULAR ENDOTHELIAL GROWTH FACTOR REFINED TO 1.93 ANGSTROMS RESOLUTION | homo-2-mer | 100 | ||||
| DISULFIDE DEFICIENT MUTANT OF VASCULAR ENDOTHELIAL GROWTH FACTOR A (C51A and C60A) | homo-2-mer | 97.89 | ||||
| VEGF-A 13:107 crystallized with 2C bicyclic peptide | homo-2-mer | 100 | 1×NH2; 1×MPD; 5×ACY; | |||
| Crystal Structure of Vascular Endothelial Growth Factor (VEGF8-109) with one copy of HH4, an alpha/… | homo-2-mer | 100 | ||||
| Dual specific bH1 Fab in complex with VEGF | homo-2-mer | 100 | ||||
| STRUCTURE OF HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR | homo-2-mer | 100 | ||||
| DISULFIDE DEFICIENT MUTANT OF VASCULAR ENDOTHELIAL GROWTH FACTOR A (C57A and C102A) | homo-2-mer | 97.87 | ||||
| Disulfide deficient mutant of vascular endothelial growth factor A (C61A and C104A) | homo-2-mer | 97.85 | ||||
| Structure of the Neuropilin-1/VEGF-A complex | homo-2-mer | 100 | 1×PO4; | |||
| Heparin-binding Domain from Vascular Endothelial Growth Factor | monomer | 100 | ||||
| HEPARIN-BINDING DOMAIN FROM VASCULAR ENDOTHELIAL GROWTH FACTOR, NMR, 20 STRUCTURES | monomer | 100 | ||||
| HEPARIN-BINDING DOMAIN FROM VASCULAR ENDOTHELIAL GROWTH FACTOR, NMR, MINIMIZED AVERAGE STRUCTURE | monomer | 100 | ||||
2 SWISS-MODEL models
| Template | Oligo-state | QMEAN | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|
| 8uwz.1.D | monomer | 0.71 | 100.00 | |||
| 1kmx.1.A | monomer | 0.68 | 96.15 | |||
27 SWISS-MODEL models built on isoform sequence
| Isoform | Template | Oligo-state | QMEAN | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|---|
| Isoform 1 | 8uwz.1.D | monomer | 0.75 | 99.13 | |||
| Isoform 1 | 1kmx.1.A | monomer | 0.65 | 96.15 | |||
| Isoform 2 | 8uwz.1.D | monomer | 0.77 | 100.00 | |||
| Isoform 2 | 4deq.1.B | monomer | 0.64 | 96.15 | |||
| Isoform 3 | 8uwz.1.D | monomer | 0.76 | 100.00 | |||
| Isoform 3 | 4deq.1.B | monomer | 0.66 | 96.15 | |||
| Isoform 4 | 8uwz.1.D | monomer | 0.78 | 100.00 | |||
| Isoform 4 | 4deq.1.A | homo-2-mer | 0.58 | 65.17 | |||
| Isoform 5 | 8uwz.1.D | monomer | 0.78 | 100.00 | |||
| Isoform 5 | 4deq.1.B | monomer | 0.57 | 56.34 | |||
| Isoform 6 | 8uwz.1.D | monomer | 0.78 | 99.13 | |||
| Isoform 8 | 8uwz.1.D | monomer | 0.78 | 100.00 | |||
| Isoform 8 | 4deq.1.B | monomer | 0.56 | 62.65 | |||
| Isoform 9 | 8uwz.1.D | monomer | 0.81 | 99.17 | |||
| Isoform 10 | 8uwz.1.D | monomer | 0.82 | 100.00 | |||
| Isoform 11 | 6t9d.1.C | monomer | 0.76 | 100.00 | |||
| Isoform 11 | 4deq.1.A | homo-2-mer | 0.62 | 65.17 | |||
| Isoform 12 | 5fv2.1.C | monomer | 0.71 | 100.00 | |||
| Isoform 14 | 8uwz.1.D | monomer | 0.71 | 100.00 | |||
| Isoform 14 | 1kmx.1.A | monomer | 0.66 | 96.15 | |||
| Isoform 15 | 6t9d.1.C | monomer | 0.77 | 100.00 | |||
| Isoform 15 | 4deq.1.B | monomer | 0.58 | 62.65 | |||
| Isoform 16 | 8uwz.1.D | monomer | 0.69 | 100.00 | |||
| Isoform 16 | 1kmx.1.A | monomer | 0.69 | 96.15 | |||
| Isoform 17 | 6t9d.1.C | monomer | 0.77 | 100.00 | |||
| Isoform 17 | 4deq.1.B | monomer | 0.59 | 56.34 | |||
| Isoform 18 | 5fv2.1.C | monomer | 0.67 | 97.27 | |||